Rhythm-drug suitability
Dronedarone: permanent AF and recent heart-failure decompensation matter
Not every medicine used for atrial fibrillation is suitable for every AF pattern. Multaq is contraindicated in permanent AF and in specified high-risk heart-failure settings; sinus rhythm on an old ECG does not settle the current check.
Sources checked October 13, 2026. Independent educational content, not NABP exam questions or individual treatment advice.
Identify the intended rhythm strategy
The indication concerns patients in sinus rhythm with a history of paroxysmal or persistent AF. The label contraindicates permanent AF, meaning patients whose sinus rhythm will not or cannot be restored. A chart that simply says AF leaves a load-bearing gap.
The pharmacist should clarify whether restoration of sinus rhythm remains the plan. An old successful cardioversion does not prove the current rhythm strategy, and a routine refill does not itself document eligibility.
Separate the heart-failure contraindication
Symptomatic heart failure with recent decompensation requiring hospitalization, or NYHA class IV symptoms, is independently contraindicated. The boxed warning describes increased death risk in that population. A patient does not need permanent AF for this concern to matter.
Do not recast the warning as a blanket ban on every historical mention of heart failure. The case details determine whether the specified contraindication applies. When the history is unclear, recover the recent admission and current clinical assessment rather than guessing.
Keep rhythm monitoring in the ongoing plan
The label calls for rhythm monitoring no less often than every three months. If a patient is in AF, cardioversion may be considered if clinically indicated or Multaq discontinued. Those choices belong to the treating team; a pharmacist identifies the need for timely review.
The medicine is not an anticoagulation replacement. The label also requires appropriate antithrombotic therapy before and throughout use. A rhythm-drug refill must not be used to infer that stroke prevention has been addressed.
Check interactions before defending continuation
Multaq has contraindications involving strong CYP3A inhibitors, QT-prolonging medicines and other class I or III antiarrhythmics. Its digoxin interaction and bradycardia concerns also need reconciliation. A correct rhythm indication is only one part of suitability.
The fictional case asks whether continuation can be assumed safe. It does not direct an individual to stop treatment without a plan or diagnose their current rhythm from a symptom. New dyspnea, edema or palpitations require clinical assessment.
A worked case
A patient taking Multaq is now documented as having permanent AF with no further cardioversion planned. They were also recently hospitalized for decompensated symptomatic heart failure. A draft approves continuation because the medicine was prescribed before the admission. Assess it.
- Permanent AF is a labeled contraindication.
- Recent decompensated symptomatic heart failure requiring hospitalization is a separate contraindication.
- Prior prescribing does not override the changed current state.
Answer: The new clinical state conflicts with two labeled contraindications. The treating team must review the plan promptly.
Try it before reading the answer
Write the key fact, decision and safety check first. These are original practice exercises, not recalled exam items.
1. Does permanent AF fit the cited Multaq indication?
No. It is contraindicated.
2. How often does the label call for rhythm checks?
At least every three months.
3. Does a rhythm medicine replace appropriate antithrombotic therapy?
No.
Continue learning
Put the topic into a study planSources and scope
Source dates and limits matter. Follow the current official source for clinical or regulatory decisions. Examples are simplified teaching cases, not prescribing, diagnostic or compounding instructions. Check the full current guidance and individual clinical context.